Overview

Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)

Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a reduced intensity (RI) (non-myeloablative) chemoimmunotherapy followed by Allogeneic Stem Cell Transplantation AlloSCT (matched family donors and matched unrelated cord blood donors) will be well tolerated.
Phase:
Phase 1
Details
Lead Sponsor:
New York Medical College
Treatments:
Alemtuzumab
Busulfan
Fludarabine
Fludarabine phosphate
Vidarabine